218 related articles for article (PubMed ID: 22912551)
1. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
Tonus C; Sellinger M; Koss K; Neupert G
World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
[TBL] [Abstract][Full Text] [Related]
2. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
3. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.
Nasir Kansestani A; Zare ME; Tong Q; Zhang J
Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276
[TBL] [Abstract][Full Text] [Related]
4. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
5. Stool DNA testing for early detection of colorectal cancer: systematic review using the HTA Core Model
Stürzlinger H; Conrads-Frank A; Eisenmann A; Invansits S; Jahn B; Janzic A; Jelenc M; Kostnapfel T; Mencej Bedrac S; Mühlberger N; Siebert U; Sroczynski G;
Ger Med Sci; 2023; 21():Doc06. PubMed ID: 37426885
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
Haug U; Hundt S; Brenner H
Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
[TBL] [Abstract][Full Text] [Related]
7. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
[TBL] [Abstract][Full Text] [Related]
8. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
9. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
11. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention.
Koss K; Maxton D; Jankowski JA
Colorectal Dis; 2008 Mar; 10(3):244-8. PubMed ID: 17784868
[TBL] [Abstract][Full Text] [Related]
12. Validation of Faecal Pyruvate Kinase Isoenzyme Type M2 (Faecal M2PK Quick) Test in Detection of Colorectal Adenoma and Adenocarcinoma Among High-Risk Malaysian Population.
Mohd Suan MA; Ng YZ; Henry GF; Md Said R; Kollanthavelu S; Mustapha MI; Hoe CH; Lee CK; Rajamanickam P; Ismail I; Chan HK; Abu Hassan MR
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3183-3186. PubMed ID: 37774070
[TBL] [Abstract][Full Text] [Related]
13. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
[TBL] [Abstract][Full Text] [Related]
14. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
15. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
[TBL] [Abstract][Full Text] [Related]
16. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer.
Hardt PD; Mazurek S; Toepler M; Schlierbach P; Bretzel RG; Eigenbrodt E; Kloer HU
Br J Cancer; 2004 Aug; 91(5):980-4. PubMed ID: 15266315
[TBL] [Abstract][Full Text] [Related]
17. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors.
Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS
Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621
[TBL] [Abstract][Full Text] [Related]
19. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
20. The Use of M2-Pyruvate Kinase as a Stool Biomarker for Detection of Colorectal Cancer in Tertiary Teaching Hospital: A Comparative Study.
Che Alhadi S; Wan Zain WZ; Zahari Z; Md Hashim MN; Syed Abd Aziz SH; Zakaria Z; Wong MP; Zakaria AD
Ann Coloproctol; 2020 Dec; 36(6):409-414. PubMed ID: 32972105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
